Free Trial
→ Out of 18,347 Cryptocurrencies... This is the ONLY One (From Crypto 101 Media) (Ad)tc pixel

TuHURA Biosciences (NASDAQ:HURA) Stock Rating Upgraded by Wall Street Zen

Written by MarketBeat
Updated September 23, 2025
TuHURA Biosciences logo with Medical background

Key Points

  • TuHURA Biosciences has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, while Brookline Capital Management rated it as a "strong-buy."
  • The stock currently holds an average rating of "Buy" with a consensus target price of $12.67.
  • In its latest earnings report, TuHURA posted a loss of ($0.21) earnings per share, missing analysts' expectations by ($0.07).
  • Interested in TuHURA Biosciences? Here are five stocks we like better.

Wall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Brookline Capital Management raised shares of TuHURA Biosciences to a "strong-buy" rating in a research note on Monday, June 23rd. Two analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $12.67.

Check Out Our Latest Report on TuHURA Biosciences

TuHURA Biosciences Trading Up 3.1%

Shares of HURA stock traded up $0.08 on Friday, reaching $2.63. 28,814 shares of the stock were exchanged, compared to its average volume of 300,033. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $8.40. The firm has a 50 day moving average of $2.68 and a two-hundred day moving average of $3.03.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07).

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HURA. JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences during the second quarter worth approximately $27,000. Intech Investment Management LLC acquired a new position in shares of TuHURA Biosciences during the second quarter worth approximately $29,000. Invesco Ltd. acquired a new position in shares of TuHURA Biosciences during the second quarter worth approximately $30,000. Merck & Co. Inc. acquired a new position in shares of TuHURA Biosciences during the second quarter worth approximately $31,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TuHURA Biosciences during the second quarter worth approximately $31,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

Featured Stories

Analyst Recommendations for TuHURA Biosciences (NASDAQ:HURA)

Should You Invest $1,000 in TuHURA Biosciences Right Now?

Before you consider TuHURA Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.

While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.